三棱丸通过S1P/S1PR1-Akt轴调控鞘脂代谢抑制子宫内膜异位症
本研究以自体移植法建立大鼠子宫内膜异位症模型,采用血清代谢组学与网络药理学探讨三棱丸的作用机制。结果显示三棱丸可抑制异位病灶生长与纤维化,调节76种血清代谢物,并通过S1P/S1PR1-Akt轴下调TGF-β、SphK2、S1P、S1PR1表达及p-Akt/Akt比值。
要点
- 三棱丸可抑制大鼠子宫内膜异位症病灶生长及纤维化。
- 三棱丸调节鞘脂信号等代谢通路及76种血清代谢物。
- 三棱丸下调S1P/S1PR1-Akt轴相关蛋白及p-Akt/Akt比值。
核心结论
- 三棱丸通过调控鞘脂代谢经S1P/S1PR1-Akt轴发挥治疗子宫内膜异位症模型大鼠的作用。
研究设计与样本
- 采用自体移植法建立大鼠子宫内膜异位症模型,设空白对照、模型、三棱丸高、中、低剂量组及地诺孕素阳性对照组,给药4周。
主要发现
- 三棱丸抑制大鼠异位病灶生长并抑制纤维化。
- 血清代谢组学鉴定出三棱丸治疗组76种显著代谢物,涉及鞘脂信号、酪氨酸代谢、脂肪酸降解、花生四烯酸代谢、丙酮酸代谢、亚油酸代谢及甘油磷脂分解等通路。
- 分子对接与SPR亲和分析显示阿魏酸、蓬莪术环氧酮、姜黄素、莪术醇、莪术二酮等化合物与SphK2、S1PR1、Akt存在结合。
- 与模型组相比,三棱丸治疗显著下调异位内膜组织TGF-β、SphK2、S1P、S1PR1蛋白表达,并显著降低p-Akt/Akt比值。
临床怎么用
- 本研究为动物实验机制探讨,尚不能直接转化为临床用药推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Endometriosis is a gynecological disorder characterized by chronic pelvic pain and infertility in women. The traditional herbal medicine Sanleng Wan (SLW) is composed of Curcuma phaeocaulis Valeton (Chinese name: Ezhu) and Sparganium stoloniferum (Buch.-Ham. ex Graebn.) Buch.-Ham. ex Juz. (Chinese name: Sanleng), has been recognized for its therapeutic potential in managing gynecological conditions, including endometriosis. In numerous traditional Chinese medicine prescriptions, SLW is classified as either the "principal drug" or the "minister drug." However, the extent to which the therapeutic effects of SLW are mediated through the modulation of serum metabolites and associated molecular targets remains unclear. AIM OF THE STUDY: This study aimed to elucidate the potential mechanism by which SLW inhibits endometriosis, utilizing serum metabolomics, network pharmacology, molecular docking, SPR affinity analysis and preliminary in vivo validation. MATERIALS AND METHODS: A rat model of endometriosis was established using the autotransplantation method. The animals were divided into blank control, model, high-, middle-, and low-dose SLW groups, and the dienogest-treated group as a positive control. SLW or dienogest was administered for 4 weeks. Fibrosis in the lesions was assessed using Masson staining. Serum metabolomics analysis was conducted to investigate the effects of SLW on serum metabolites in endometriosis model rats, and metabolic pathways were analyzed using the MetaboAnalyst database. A metabolites-targets-pathways network was constructed using Cytoscape software. Additionally, surface plasmon resonance (SPR)-based binding affinity analysis was conducted to investigate potential direct interactions between the bioactive compounds and key proteins. Five major principal compounds (zederone, curcumin, ferulic acid, curcumol, and curdione) were evaluated for the binding capabilities with three proteins: sphingosine kinase 2 (SphK2), sphingosine-1-phosphate receptor 1 (S1PR1), and AKT serine/threonine kinase (Akt). Subsequently, the expression levels of transforming growth factor-β (TGF-β), sphingosine-1-phosphate (S1P), S1PR1, SphK2 and Akt, and phosphorylated Akt (p-Akt) in ectopic endometrium tissue were quantified using Western blot analysis. RESULTS: In a rat model, SLW inhibited the growth of endometriotic lesions and suppressed fibrosis. Metabolomic analysis revealed distinct serum metabolites associated with SLW treatment. A total of 76 significant metabolites were identified in the serum of the SLW-treated group, including L-threonine, (S)-homostachydrine, DL-arginine, and L-homoarginine, among others. These metabolites were involved in various metabolic pathways, including sphingolipid signaling, tyrosine metabolism, fatty acid degradation, arachidonic acid metabolism, pyruvate metabolism, linoleic acid metabolism, and glycerophospholipid catabolism. Molecular docking and SPR affinity analysis demonstrated that compounds including ferulic acid, zederone, curcumin, zedrone, curcumol, and curdione contribute to the modulation of targets within the S1P/S1PR1-Akt signaling axis. Notably, compared with the model endometriosis group, SLW treatment significantly downregulated the protein expression levels of TGF-β, SphK2, S1P, and S1PR1 in ectopic endometrial tissues of rats, while markedly reducing the p-Akt/Akt ratio. These findings shed light on the potential molecular mechanisms underlying SLW's therapeutic effects. CONCLUSIONS: This study, utilizing serum metabolomics and network pharmacology, demonstrates the therapeutic effects of SLW in endometriosis model rats by modulating sphingolipid metabolism via the S1P/S1PR1-Akt axis, thereby enhancing understanding of its underlying mechanisms of action.
引用
- Fu Z, Zhou H, Liu H, et al. Sanleng Wan inhibits endometriosis progression by regulating sphingolipid metabolism via the S1P/S1PR1-Akt axis based on serum metabolomics and network pharmacology. J Ethnopharmacol. 2025. PMID: 40523453. doi:10.1016/j.jep.2025.120153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。